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Abstract: Gynecologic cancers cause over 600,000 deaths annually in women worldwide.
The development of chemoresistance after initial rounds of chemotherapy contributes to tumor
relapse and death due to gynecologic malignancies. In this regard, cancer stem cells (CSCs), a
subpopulation of stem cells with the ability to undergo self-renewal and clonal evolution, play a key
role in tumor progression and drug resistance. Aldehyde dehydrogenases (ALDH) are a group of
enzymes shown to be robust CSC markers in gynecologic and other malignancies. These enzymes
also play functional roles in CSCs, including detoxification of aldehydes, scavenging of reactive
oxygen species (ROS), and retinoic acid (RA) signaling, making ALDH an attractive therapeutic
target in various clinical scenarios. In this review, we discuss the critical roles of the ALDH in driving
stemness in different gynecologic malignancies. We review inhibitors of ALDH, both general and
isoform-specific, which have been used to target CSCs in gynecologic cancers. Many of these inhibitors
have been shown to be effective in preclinical models of gynecologic malignancies, supporting further
development in the clinic. Furthermore, ALDH inhibitors, including 673A and CM037, synergize with
chemotherapy to reduce tumor growth. Thus, ALDH-targeted therapies hold promise for improving
patient outcomes in gynecologic malignancies.
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1. Introduction
The first line of therapy for most gynecologic cancers includes surgery, followed by chemotherapy
and radiation [1]. However, in the majority of cases, these conventional therapies do not completely
eliminate the malignant cells. The primary reason for high mortality is recurrence and subsequent
metastasis caused by the residual population of cancer cells [2,3]. The cells that survive after the first
line of treatment and contribute to cancer recurrence are known as CSCs [4,5]. The CSC theory states
that the tumor is a heterogeneous mass, and within the tumor exists a hierarchy of cells, with CSCs
at the apex [6]. Lapidot et al. first proposed the idea that a set of specialized cells present within
the tumor can sustain and repopulate the tumor [7]. CSCs have since been reported in gynecologic
malignancies (Table 1).
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Table 1. Cancer stem cells reported in gynecologic malignancies.
Gynecologic Malignancy Cancer Stem Cells References
Cervical cancer Reported in literature [8–10]
Uterine cancer Reported in literature [11–14]
Ovarian cancer Reported in literature [15–19]
Vulvar cancer Reported in literature [20]
Vaginal cancer No published reports -
CSCs are resistant to conventional chemotherapy due to several mechanisms. Chemotherapeutic
drugs, primarily platinum-based drugs, form DNA crosslinks, killing cells by causing DNA damage
in rapidly-dividing cells [21]. However, CSCs are resistant to DNA damage due to a number of
properties, including slow cycling, reduced uptake of drugs and increased drug efflux due to the
high expression of a class of non-selective drug transporters called adenosine triphosphate binding
cassette (ABC) ATPases [22]. Furthermore, CSCs have enhanced DNA repair due to overexpression of
repair pathways such as ataxia-telangiectasia-mutated (ATM), ataxia telangiectasia and rad3-related
(ATR), checkpoint kinase 1 (Chk1), poly(ADP-ribose) polymerase 1 (PARP1), and RAD51 [23] that
protect CSCs from drugs designed to cause cancer cell death by inducing DNA damage. As a quiescent
population [24], CSCs are further protected by platinum-induced DNA damage. Thus, it is necessary
to target CSCs specifically to achieve a better prognosis in patients. Of the different CSC markers
identified to date in gynecologic malignancies [10–20,22,23], ALDH is widely recognized as a highly
robust CSC marker across the vast majority of cancer types, including gynecologic CSCs. Furthermore,
ALDH holds the distinction of having potential functional importance in the maintenance of CSCs [25],
making it an attractive target for eradicating CSC in the therapeutic maintenance setting for gynecologic
malignancies such as ovarian cancer.
The ALDH superfamily comprises 19 members, all of which are involved in regulating crucial
functions in normal as well as cancer stem cells [13–19]. The primary role of ALDH enzymes is to
metabolize reactive aldehydes produced by various biological processes [26] (Figure 1).
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retinaldehyde into retinoic acid, which promotes stemness, growth, and survival in c cer stem cells.
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Detoxification of aldehydes is critical for cellular health, as aldehyde toxicity can lead to DNA
damage, impaired cellular homeostasis, and cell death [27]. Another vital role of ALDH is in
retinoic acid metabolism, which is crucial for gene expression and morphogenesis during embryonic
development growth, cellular differentiation, and homeostasis of vertebrates [28–30]. Cytosolic class I
ALDH enzymes catalyze the NAD-dependent oxidation of both all-trans-retinal and 9-cis-retinal to
all-trans-retinoic acid and 9-cis-retinoic acid [31,32]. ALDH also plays a role in reactive oxygen species
(ROS) scavenging and thereby reducing oxidative stress in stem cells [33] (Figure 1).
In cancer cells, ALDH contributes to chemoresistance via different mechanisms [34]. ALDH isoforms,
ALDH1A1, and ALDH3A1 are both involved in the metabolism of the cancer drug cyclophosphamide,
metabolizing the active compound to a less active form and contributing to drug resistance [35].
When combined with cyclophosphamide in ALDH3A1high cell lines, ALDH3A1 inhibitors have been
shown to increase sensitivity to the mafosphamide (cyclophosphamide analog) [34]. Another mechanism
by which ALDH protects cancer cells is by reducing ROS-mediated oxidative stress [36] (Figure 1). As a
consequence of this, ALDHhigh CSCs have a lower baseline ROS level and oxidative damage than the
ALDHlow counterparts [33].
Clinically, high ALDH expression is associated with poor outcomes in several gynecologic
malignancies, including ovarian cancer (OC) [17,37–40], endometrial [41], and cervical cancer (CC) [42,43],
as well as other solid tumors including breast [44–46], lung adenocarcinoma [47], rectal [48], esophageal
squamous adenocarcinoma [49], gastric [50], colorectal [51], prostate [52], and neuroblastoma [53].
To our knowledge, there are no published reports correlating ALDH and prognosis in vulvar or
vaginal cancer. Of the 19 ALDH isoforms, ALDH1 is the primary isoform implicated in CSCs of solid
tumors [54]. The advent of the Aldefluor assay has stimulated research on CSCs expressing high ALDH.
Briefly, the Aldefluor assay can be used to detect cells expressing high levels of ALDH. The Aldefluor
reagent Bodipy- aminoacetaldehyde (BAAA) is converted into BODIPY-aminoacetate (BAA), in the
presence of ALDH, and retained inside the cells. ALDH activity of the cells is directly proportional to the
fluorescence intensity [55]. The assay can detect nine ALDH isoforms, with ALDH1 as the predominant
isoform contributing to ALDHhigh cells [56]. These provide a strong rationale for targeting ALDH to
eliminate CSCs in gynecologic malignancies. A recent review by Dinavahi et al. elegantly highlights the
inhibitors developed to target ALDH from a pharmacologic perspective in different cancer types [57].
In this review, we briefly discuss the gynecologic malignancies affecting women worldwide and
review the findings about ALDH in relation to the gynecologic CSCs. We assess the agents targeting
ALDH directly or indirectly in the different gynecologic cancers. Finally, we discuss current challenges
associated with targeting ALDH in CSCs in gynecologic cancers.
2. Gynecologic Malignancies: An Overview
Gynecologic malignancies are cancers that originate in the female reproductive system. Each year
over 1.3 million women are diagnosed with gynecologic cancers worldwide, and over 600,000 deaths
are caused due to gynecologic cancers [58]. There are five types of gynecologic cancers based on the
site of origin, namely ovarian, cervical, uterine, vaginal, and vulvar (Figure 2). Although these cancers
are commonly grouped, each has unique features, symptoms, and treatment options [59].
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2.1. Cervical Cancer
Cervical cancer (CC) is the deadliest of the gynecologic cancers, causing more deaths worldwide
compared to all other cancers of the female reprodu tive system [58]. In 2018, 569,847 women er
diagnos with CC worldwide. CC clai ed 311,365 lives [58] (Figure 2). CC is divided int two main
subtypes: squamous cel carcinoma (SCC) and adenocarcinoma. SCC originates from the squa ous
cells lining the ect cervix (part of the cervix extending utwards to the vagina) nd is the most prevalent
type, accounting for about 80% of CC.
2.2. Uterine Cancer
According to the statistics by the International Agency for Research on Cancer (IARC), approximately
382,069 new cases of cancer of the uterus (uterine body or corpus) were diagnosed in 2018, and about
89,929 women died from uterine cancer [58] (Figure 2). Uterine cancer is classified into two main types:
endometrial cancer (EC) and uterine carcinosarcoma. EC are further divided into type I and type II
malignancies [61]. Type I cancers are the most common and affect both pre- and postmenopausal
women and are generally low grade, well-differentiated tumors of endometrioid histology [61]. Most EC
is diagnosed at initial stages, making it possible to treat the disease ith cytoreductive surgery [62].
However, when iagnosed with extrauterine spread, the relapse rate is high [62].
2.3. Ovarian Cancer
Ovarian cancer (OC) is a deadly gynecologic malignancy and is the second leading cause of
death due to gynecologic cancers worldwide [58]. About 295,414 women were diagnosed with OC in
2018, and the disease caused about 184,799 deaths globally [58] (Figure 2). The most common type of
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OC is epithelial OC, which is categorized into four histological subtypes, namely serous, clear cell,
endometrioid, and mucinous carcinomas [63]. Of these, the most significant contributor to high
mortality and reduced survival rate is high grade serous ovarian cancer (HGSOC) [64]. In most women,
the diagnosis is made only at advanced stages, after the tumor has spread beyond the ovary [64].
HGSOC is initially highly responsive to platinum or taxane-based chemotherapy; however, more than
80% of patients experience disease relapse and progression. Chemoresistant HGSOC is uniformly
fatal [64]. The 5-year survival rate for HGSOC is only about 30% and has not improved in the last
several decades [65].
2.4. Vulvar Cancer
Vulvar cancer is a rare malignancy of the vulva, accounting for about 6% of cancers of female
reproductive organs and less than 1% of all cancers in women [60]. Globally, 44,235 new cases of vulvar
cancer were diagnosed in 2018, and about 15,222 women died due to vulvar cancer [58] (Figure 2).
Vulvar cancer includes cancers of the inner and outer lips of the vagina, the clitoris, and the opening of
the vagina and vaginal glands. The main subtypes of vulvar cancer are SCC, adenocarcinoma, sarcoma,
and basal cell carcinoma, amongst which the most prevalent is SCC [66]. Surgery is the primary mode
of treatment for vulvar cancer, followed by radiation or chemotherapy [67].
2.5. Vaginal Cancer
Vaginal cancer is an uncommon cancer type and comprises about 1% of all gynecologic malignancies [60].
According to the IARC, 17,600 cases of vaginal cancer were diagnosed in 2018, and the disease caused
about 8062 deaths worldwide [58] (Figure 2). Approximately 85% of vaginal cancers are malignancies
in the squamous cell lining. At an early stage, this cancer is curable by surgery and radiation.
However, only radiation therapy is known to be effective in advanced stage vaginal cancer [68].
3. ALDH in Gynecologic Cancers
3.1. ALDH and Cervical Cancer
In tissue specimens from patients with cervical SCC or cervical intraepithelial neoplasia (CIN)
II-III, high ALDH expression was observed immunohistochemically [43]. Interestingly, peripheral
blood (plasma) samples from the same patients had increased ALDH1A1 expression when compared
with samples from healthy patients [43]. In patients with invasive SCC, ALDH1 expression correlated
with lymph nodal metastasis and disease recurrence [69]. These data indicate that ALDH1 can be
used as a reliable biomarker for the identification of cervical CSCs [70]. The ALDHhigh cells isolated
from these cancers showed high gene and protein expression of stemness transcription factors Nanog,
sex determining region Y-box2 (Sox2), octamer-binding transcription factor (Oct4), and twist-related
protein 1 (Twist1) [43]. However, the exact mechanism by which ALDH regulates stemness in cervical
cancer remains incompletely understood.
3.2. ALDH and Uterine Cancer
In EC, the most prevalent type of uterine cancer, altered stemness related pathways, including Wnt
and β-catenin, support a role for CSCs [71]. Furthermore, ALDHhigh subpopulation of cells has been
demonstrated to be CSCs in EC [71]. The ALDHhigh cells isolated from primary endometrial tumors
were highly tumorigenic and resistant to chemotherapeutic drugs and showed increased invasive
ability compared to the ALDHlow cells [72].
In patients with uterine endometrioid carcinosarcoma, high ALDH1 expression predicted poor
prognosis, lymphatic invasion, recurrence, and low overall survival [73]. ALDHhigh CSCs cells
have distinct stem-like properties, such as high expression of stem-cell markers BMI1, HEY1, HES1,
and adhesive molecule CD44 [41,74,75]; in addition, reduced expression of differentiation markers,
enhanced migration, high tumorigenicity, and self- renewal ability were reported [76]. When EC cells
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were sorted using flow cytometry and cultured in vitro, ALDHhigh cells yielded both ALDHhigh and
ALDHlow cells, whereas ALDHlow cells only yielded ALDHlow cells [72]. These results demonstrated
that endometrial CSCs divide asymmetrically, in agreement with the CSC hypothesis. Furthermore,
when injected into mice subcutaneously, ALDHhigh endometrial cells formed larger tumors more
rapidly than the ALDHlow cells [72], demonstrating that CSCs were able to repopulate the entire
endometrial tumor mass. Based on these studies ALDH1 serves as both a marker for identifying
endometrial CSCs and a therapeutic target, based in its functional importance in the disease.
3.3. ALDH and Ovarian Cancer
Cancer relapse after surgery and chemotherapy is common in OC, and CSCs are strongly associated
with OC relapse [77]. ALDHhigh cells are widely accepted as CSCs in OC, as demonstrated by us
and others [17,37–39,78–83]. ALDHhigh ovarian cancer stem cells (OCSCs) exhibit classic stem cell
characteristics, such as being highly chemoresistant and enriched in residual xenografts after platinum
therapy [78,79,83]. Upregulation of stemness genes such as Sox2, Kruppel like factor 4 (Klf4), Nanog,
and downregulation of differentiation genes such as homeobox A10 (HOXA10) and homeobox A11
(HOXA11), were reported in ALDHhigh cells [83]. ALDHhigh cells demonstrated enhanced ability to
form spheroids in low attachment conditions in vitro [75,80].
In OCSCs, of the 19 ALDH isoforms, ALDH1A1 was highly correlated with chemotherapy
resistance [78,79,81,82,84,85]. Expression of ALDH1A1 was 100-fold higher in OC cells selected for
taxane-resistance in vitro, and ALDH1A1 knockdown sensitized the resistant cells to chemotherapy [82].
ALDH1A1 expression was higher in residual tumors after the first round of chemotherapy compared to
tumors from untreated patients [86], demonstrating enrichment of OCSC post-treatment. In addition
to ALDH1A1, CD133 serves as a robust marker for OCSC when used in combination with ALDH [17].
In this regard, Silva et al. observed that as low as 11 ALDH and CD133 double-positive cells
resulted in tumor induction in mice [17]. Moreover, in tumors harvested during debulking
surgeries, ALDHhighCD133+ cells correlated with reduced disease-free and overall survival in OC
patients [17]. ALDHhigh cells were highly metastatic with enhanced invasive ability and were resistant
to apoptosis [87]. These data provide a strong rationale for targeting ALDHhigh cells in OC [37].
3.4. ALDH and Vulvar Cancer
Vulvar cancer is an uncommon type of tumor in women. To date, one study on ALDH in
this gynecologic cancer has been reported. ALDH1 expression in vulvar squamous cell carcinoma,
normal vulvar epithelium, and stromal tissues in a cohort of 154 patients was studied [88]. Based on
clinicopathological studies, high ALDH1 expression correlated with favorable prognosis and can be
considered a potential marker for differentiated vulvar cells [88]. However, this report is contradictory
to the correlation of ALDH with poor prognosis in other gynecologic cancers, suggesting that ALDH
expression could be a tissue-specific marker for CSCs.
4. ALDH-Targeted Therapies for Gynecologic Cancers
4.1. Agents Directly Targeting ALDH
The identification of ALDHhigh cells as CSCs, first reported in breast cancer tissue [89], is widely
accepted as a CSC marker in most other tumors [90–99]. Landen et al. was the first to demonstrate
proof-of-concept for targeting ALDHhigh cells in a gynecologic cancer [79]. In ovarian CSC, use of small
interfering ribonucleic acid (siRNA) to silence ALDH1A1 in an orthotopic mouse model sensitized
both platinum and taxane resistant OC cell lines to chemotherapy [79]. In this section, we discuss the
inhibitors used to target ALDH in gynecologic malignancies (Table 2).
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Table 2. ALDH inhibitors in gynecologic malignancies.
Compound ALDH IsoformSpecificity
Gynecologic
Malignancy Preclinical Studies References
Disulfiram ALDH2, ALDH1 OvarianCervical
Orally bioavailable. Limited
in vivo efficacy in ovarian
cancer mouse model
[100–103]
DEAB
ALDH1A1,
ALDH1A2,
ALDH1A3,
ALDH1B1,
ALDH2,
ALDH3A1,
ALDH5A1
Ovarian
Endometrial No in vivo studies found [80,82,104,105]
ATRA
ALDH1,
ALDH1A1,
ALDH1A3
Ovarian
Cervical
Reduced in vivo
tumorigenesis in ovarian
cancer
[106–108]
NCT 501 ALDH1A1 OvarianEndometrial
Halted tumor re-growth in
orthotropic ovarian cancer
xenograft model
[85,109,110]
NCT-505
NCT-506 ALDH1A1 Ovarian
Orally bioavailable
No weight loss or mortality in
pilot toxicity studies
[108]
CM037 (A37) ALDH1A1 OvarianEndometrial
Ineffective in vivo likely due
to low aqueous solubility
Non-toxic to mice at 20 mg/kg
[84,110,111]
13g
13h ALDH1A Ovarian
Showed excellent in vivo
efficacy on i.p. administration
in OC mouse model
[112]
673A
ALDH1A1,
ALDH1A2,
ALDH1A3
Ovarian
Highly synergistic with
chemotherapy in reducing
tumor initiation and
increasing tumor eradication
[80]
4.1.1. Disulfiram
Disulfiram (DSF) is an orally bioavailable ALDH inhibitor, well known for its effectiveness in the
treatment of alcohol addiction [113,114]. Though DSF is primarily an inhibitor for ALDH2, DSF also
inhibits ALDH1 isozymes, which are overexpressed in CSCs, providing the rationale for repurposing
DSF as an anti-cancer drug. Anti-neoplastic activities of DSF in several malignancies have been
described [115–120]. DSF works by elevating intracellular ROS levels, thus driving the CSCs towards
apoptosis [121]. DSF/Copper complex was shown to target ALDH1A1 and inhibit cancer recurrence
primarily driven by ALDHhigh CSCs [100]. In OC, DSF exhibited cytotoxicity comparable to cisplatin,
while having a limited effect on the viability of non-neoplastic cells. Cell death due to DSF was
partly due to programmed cell death, and an additive effect, when combined with chemotherapy,
was observed [101] (Table 2). Interestingly, DSF depleted CD44+ OCSCs in vitro but not CD133+ cells
in vitro. However, DSF did not show significant activity in vivo [101]. In another study, DSF induced
cell death in OC by promoting a pro-oxidative intracellular environment, causing irreversible damage
to the cancer cells within a few hours of treatment via the induction of heat shock proteins [102].
In the treatment of localized CC, DSF-loaded thermoplastic vaginal rings were shown to be
effective in vitro [103] (Table 2). The vaginal rings are a minimally invasive treatment option as well
as require low drug concentration compared to oral delivery. However, vaginal rings require further
in vivo and clinical validation and are currently not a therapeutic option [103]. Presently, there are no
ongoing clinical trials using DSF to treat gynecologic malignancies. Limited in vivo efficacy of DSF and
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lack of selectivity has limited its use as an ALDH inhibitor and CSC-targeted agent. To our knowledge,
there are no published reports on the use of DSF in other gynecologic malignancies.
4.1.2. 4-Diethylaminobenzaldehyde
4-Diethylaminobenzaldehyde (DEAB) is an ALDH inhibitor and a slow competitive substrate
for the enzyme [122]. DEAB has been extensively used to inhibit retinoic acid (RA) synthesis in
studying the role of retinoic acid in embryogenesis [123]. DEAB is commonly used as a negative
control in the Aldefluor assay to detect ALDHhigh CSCs [44]. In a HGSOC study, high dose
DEAB treatment preferentially depleted CD133+ ovarian CSCs [80] (Table 1). In chemoresistant
OC cell lines, DEAB treatment significantly inhibited P-glycoprotein (P-gp) protein and breast cancer
resistance protein (BRCP) transcript and protein, re-sensitizing the cell lines to chemotherapy [82].
Similarly, DEAB effectively inhibited the proliferation of spheroids generated from patient-derived
endometrial CSCs [104] (Table 2). However, it is also important to note that the selectivity of DEAB for
different ALDH isoforms is low. DEAB acts as a substrate with the highest selectivity for the isoform
ALDH3A1 expressed in stem cell populations in various tumor tissues [105]. DEAB is a substrate for
ALDH1A1 (albeit very slow) [105]. No published reports of DEAB being used to target ALDH in other
gynecologic cancers were found.
4.1.3. All-Trans Retinoic Acid (ATRA)
ATRA is an active metabolite of vitamin A and involved in many crucial signaling pathways such
as embryonic development, immune system function, reproduction, and epithelial integrity [124–126].
ATRA is commonly used as a differentiation agent in stem cell research [127,128], and several studies
have reported the use of ATRA as a differentiation agent to inhibit cancer cell growth by altering the
cell cycle progression [129–131] and to target CSCs tumorspheres in various malignancies both in vitro
and in vivo [132–136]. In OC, ATRA reduced ALDH1 expression and suppressed in vitro tumorsphere
formation, cell migration, and invasion and in vivo tumorigenesis [106] (Table 2). The mechanism of
action of ATRA was shown to be mediated through the abrogation of ALDH1/FoxM1/Notch1 signaling
in OCSCs [106]. In another study in OC cell lines, ATRA-mediated inhibition of ALDH1A1 activity led
to the re-sensitization of the resistant cells to chemotherapeutics, by downregulating the expression
of drug transporters P-gp and BCRP on the cell surface [82]. ATRA suppresses ALDH1 expression
by inhibiting nuclear factor erythroid-2-related factor 2 (Nrf-2), a transcription factor associated with
chemoresistance and cancer progression in OC [107]. Inhibition of ALDH1A1 by ATRA led to the
inhibition of the CSC-like properties and the expression of drug efflux transporters, and p62, along with
CSC markers in ALDHhigh cells [107]. In CC CSCs, ATRA reduced the percentage of ALDHhigh cells by
targeting the expression of ALDH1A1 and ALDH1A3 [108] (Table 2). There are no published reports
of ATRA being used as a therapeutic agent to target CSCs in the other gynecologic malignancies.
4.1.4. NCT-501, NCT-505, and NCT-506
To identify a specific ALDH1A1 inhibitor, Yang et al. performed a systematic medicinal chemistry
optimization of theophylline-based compounds through a miniaturized 1536-well Aldefluor assay
screen [137]. This screen identified compound NCT-501 as a specific ALDH1A1 inhibitor with enhanced
ADME properties. NCT-501 exhibited exceptional selectivity over other ALDH isozymes (ALDH1B1,
ALDH2, and ALDH3A1) (Table 2). NCT-501 is a reversible inhibitor with good in vivo pharmacological
exposure by intraperitoneal administration (i.p.); however, further development is necessary in order
to make the drug orally bioavailable [85]. In OC cells, ALDH1A1 inhibition by NCT-501 abrogated CSC
expansion induced by the silencing of a tumor suppressor DNA damage-binding protein (DDB2) [109].
Treatment with NCT-501 inhibited ALDH activity without significant cytotoxicity and reduced the
de-differentiation of non-CSC into CSC significantly [81]. In endometrial CSCs, NCT-501 caused
significant inhibition of ALDH activity, reduced spheroid cells, and caused selective cell death in
ALDHhigh cells [110].
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Medicinal chemistry optimization also led to the discovery of newly designed ALDH1A1 selective
inhibitors NCT-505 and NCT-506 [138] (Table 2). These analogs showed target engagement in a cellular
thermal shift assay (CETSA) in vitro. In a cellular context, the inhibitors inhibited spheroid formation
in an OC cell line and re-sensitized paclitaxel-resistant OC cells to cytotoxicity. These lead compounds
also exhibited enhanced selectivity over other ALDH isozymes. Pharmacokinetic studies have shown
in vivo drug exposure for NCT-505 and NCT-506 [108], establishing the potential for proof-of-concept
experiments to better understand ALDH1A1 regulation in CSCs in vivo.
4.1.5. CM037
Toward the objective of identifying a specific ALDH1A1 inhibitor, Morgan et al. developed a
high-throughput screening (HTS) platform using an in vitro NAD+ independent esterase assay. Using
this HTS platform, 64,000 compounds were screened and a potent, highly selective, and novel ALDH1A1
inhibitor CM037 (A37) was identified [111] (Table 2). In OC cells, Matei and Hurley et al. demonstrated
that CM037 significantly inhibited tumorsphere formation and CSC viability [84]. In a subsequent study
by the same group, CM037 treatment promoted DNA damage in OC cells with a corresponding increase in
DNA damage response genes. CM037 inhibited ALDH1A1, resulting in the accumulation of intracellular
ROS, DNA damage, and apoptosis [84]. In EC cells, Mori el al. demonstrated that CM037 treatment
inhibited spheroid formation and preferential death of ALDHhigh cells [110]. Thus, CM037 is a potential
therapeutic to target ALDH1A1 in CSCs in OC and EC; however, further modifications in the structure
are required to improve the in vivo stability and bioavailability of the inhibitor. No published reports on
CM037 in other gynecologic malignancies could be found in the literature.
4.1.6. 13g, 13h
A (HTS) approach by Hurley et al. identified CM039, a lead compound with high selectivity
towards ALDH1A1 [139]. A co-crystal structure of CM039 with ALDH1A1 yielded two compounds
with high selectivity towards ALDH1A1 over ALDH2 isoform, named 13g and 13h [112] (Table 2).
Both compounds significantly reduced the proliferation of ALDHhighCD133+ OCSC population in
HGSOC cell lines and showed excellent in vivo efficacy (i.p. administration) [112] and 13h synergized
with cisplatin in a patient-derived OC spheroid model [112].
4.1.7. 673A
673A, an analog of DEAB, is a pan-ALDH1A inhibitor. 673A can inhibit ALDH1A1, ALDH1A2,
and ALDH1A3, with high selectivity over ALDH2 or ALDH3. 673A preferentially killed CD133 + CSCs
by induction of necroptosis and exhibited synergy with chemotherapy in reducing tumor initiation and
promoting tumor eradication in vivo [80] (Table 2). This study confirmed the role of ALDH1A family
enzymes in chemoresistance and strengthened the hypothesis that targeting ALDH family members
can improve outcomes in patients with HGSOC.
4.2. Agents Indirectly Targeting ALDH
Indirect targeting involves inhibition of targets upstream regulators of ALDH, thus blocking the
expression of ALDH in the cells. The studies described below have taken this approach (Table 3).
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Table 3. Agents indirectly targeting ALDH in gynecologic malignancies.
Therapeutic Agent Target GynecologicMalignancy In Vivo Studies Reported References
JQ1 BRD4 Ovarian cancer
JQ1 in combination with
cisplatin improved survival of
OC bearing mice in an
orthotopic model
[140]
Anti-EMP2 IgG1 EMP2 Endometrialcancer
Reduces CSCs and secondary
tumor formation in mice [141]
PNA HOTAIR Ovarian cancer
Reduced tumor formation and
improved survival in mice with
platinum-resistant ovarian
tumor xenografts
[142]
miR-23b 3’UTR ofALDH1A1 Cervical cancer No in vivo studies reported [143]
4.2.1. JQ1
JQ1 is a thienotriazolodiazepine and a potent inhibitor that targets bromodomain-containing
protein 4 (BRD4), a transcriptional regulator for global gene expression patterns [144]. JQ1 inhibited
ALDH activity in epithelial OC cells by acting on the super-enhancer of the ALDH1A1 gene and
blocked the growth of cisplatin-resistant OC cells in vitro [140] (Table 3). In an orthotopic mouse model,
Zhang and co-workers further demonstrated that JQ1 in combination with cisplatin improved the
survival of tumor-bearing mice [140], providing compelling rationale for the use of JQ1 as a potential
therapeutic agent to target OCSCs and perhaps CSCs in other gynecologic malignancies.
4.2.2. Anti-EMP2 IgG1
In EC patients, epithelial membrane protein-2 (EMP2) correlated with disease progression and
poor survival [145]. Treatment with the Anti-EMP2 IgG1 antibody inhibited the expression and
activity of ALDH and correspondingly reduced both primary and secondary tumor load [141] (Table 3).
However, further research is required to improve drug delivery mechanisms to administer the
antibody-based treatment to patients.
4.2.3. Peptide Nucleic Acid
Non-protein coding RNAs consisting of small (<200 nucleotides) and long (>200 nucleotides)
non-coding RNAs (ncRNAs) constitute a large proportion of transcripts in the human genome.
Specifically, aberrant expression of long non-coding RNA (lncRNA) HOX antisense intergenic RNA
(HOTAIR) is associated with cancer progression and metastasis in several cancer types [146–148].
Our lab has previously reported that HOTAIR is highly expressed in chemo-resistant OC [149] and
in ALDHhigh OCSCs [142]. Targeting HOTAIR with peptide nucleic acid (PNA) inhibited ALDH1A1
levels in OCSCs in vitro and in vivo [142] (Table 3), representing a novel strategy to target lncRNAs
and subsequently ALDH1A1 in gynecologic CSCs.
4.2.4. miR-23b
Micro-RNAs (miR) are short ncRNAs involved in pathogenesis of various malignancies including
CC [150]. miR-23b was downregulated in cervical CSCs derived from tumorspheres and direct binding
of miR-23b to the 3’ untranslated region (UTR) suppressed translation of ALDH1A1 protein [143]
(Table 3). In addition, overexpression of miR-23b increased the sensitivity of cervical CSCs to
platinum-based chemotherapy [143], supporting the potential of miR-23b as an indirect approach to
target ALDH1A1 in cervical CSCs.
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4.3. Combination Therapies using ALDH Inhibitors
Several studies in OC have demonstrated the therapeutic potential of combining ALDH inhibitors with
chemotherapy. siRNA-mediated gene silencing of ALDH1A1 sensitized cisplatin and paclitaxel-resistant
OC cell lines to chemotherapy and significantly inhibited tumorigenesis in mice compared to chemotherapy
alone [79]. Treatment with an ALDH1A1 inhibitor CM037 sensitized OC spheroids to cisplatin
treatment [78]. ALDH1A family inhibitor 673A synergized with cisplatin treatment, resulting in a
30-fold reduction in cell numbers in chemotherapy-resistant OC cells compared to either therapy alone [80]
and was also shown to synergize with cisplatin to inhibit ovarian CSC proliferation [112]. Auranofin, an
inhibitor of the cellular thioredoxin system, enhanced the cytotoxic effect of DSF in OC cells [102]. This is
an excellent example of drug repositioning where a combination of anti-alcoholic disulfiram and the
anti-rheumatic auranofin may be a potential therapeutic option for recurrent OC [102]. Finally, pretreatment
with a combination of ATRA and DEAB re-sensitized ALDHhigh OCSCs to chemotherapeutic drugs
paclitaxel and topotecan [82]. In EC patient-derived spheroids, a combination of paclitaxel and ALDH
inhibitor DSF chemotherapy demonstrated synergistic inhibition of cancer progression in vivo and
in vitro [110]. Reports on combination treatments using ALDH inhibitors in the other gynecologic
malignancies were not apparent; however, published studies in OC and EC provide strong rationale for
the treatment of chemo-resistant gynecologic malignancies in general with a combination of chemotherapy
and ALDH inhibitors to achieve a better outcome in patients.
5. Challenges and Future Directions
A challenging aspect of using ALDH inhibitors to target CSCs is the broad expression of the enzyme
family in healthy tissues, especially in the liver and kidney [151]. Until recently, ALDH1A1 was thought to
be primarily responsible for the stemness phenotype. However, recent reports suggest that other isoforms,
including ALDH1A3, ALDH7A1, and ALDH3A1 [152–154], contribute to stemness, demonstrating the
need to develop additional isoform-specific inhibitors. Another challenge is in vivo activity which explains
the lack of ALDH inhibitors in ongoing clinical trials for gynecologic cancers. To date, 673A is the only
isoform-selective compound used in vivo [80]. Even with several ALDH inhibitors being developed
recently [57], it is essential to focus efforts on developing efficacious and bioavailable ALDH inhibitors
to fully understand the role of ALDH in CSC regulation in vivo. Lastly, even though the use of specific
inhibitors to target CSCs may eliminate the resistant population, it is unlikely that ALDH inhibitors will
be effective as single agents. warranting further exploration of ALDH inhibitors in combination with
cytotoxic or targeted therapies in gynecologic cancers and other malignancies.
6. Conclusions
Research on ALDH in CSCs over the past several decades has dramatically advanced the
understanding of biological processes involved in tumorigenesis and chemoresistance. Of the
several markers implicated in CSCs, ALDH is the most robust and has the advantage of having
a functional role in the maintenance and protection of CSCs. The development of new inhibitors
and repurposing of several ALDH inhibitors are promising approaches for targeting and eradicating
CSCs. However, in different malignancies, including gynecologic cancers, isoform specific ALDH
inhibitors are needed to target the full spectrum of CSCs. In addition, ALDH inhibitors with
improved pharmacokinetic properties are needed for use in the clinic for patients with gynecologic
and other malignancies.
Author Contributions: V.M. contributed to the conceptualization and writing (original draft and figure preparation,
review and editing). K.P.N. and T.D.H. contributed to conceptualization and writing (review and editing). All
authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by Indiana Clinical and Translational Science Institute (Collaboration in
Translational Research Award), Ovarian Cancer Research Alliance, and Congressionally Directed Medical Research
Programs Department of Defense Ovarian Cancer Research Program (Award Number W81XWh-17-1-0076).
Cancers 2020, 12, 961 12 of 20
Acknowledgments: The figures in this article were created using BioRender.com. We thank Tyler. C. Given for
the help with manuscript preparation.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
CSC cancer stem cells
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RA retinoic acid
ROS reactive oxygen species
ABC adenosine triphosphate binding cassette
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ATRA All-trans retinoic acid
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DDB2 DNA damage-binding protein
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